Persistent SARS-CoV-2 Reservoirs and the Pathobiology of Long COVID

Etiology, Tissue Persistence, Genomics, Clinical Manifestations, Biomarkers, and Emerging Therapeutic Strategies

John Murphy, Chief Executive Officer, The COVID-19 Long-haul Foundation

Abstract

Background

More than four years after the emergence of SARS-CoV-2, a substantial proportion of infected individuals continue to experience persistent, disabling symptoms collectively termed post-acute sequelae of SARS-CoV-2 infection (PASC) or Long COVID. Although acute COVID-19 severity has declined because of population immunity, vaccination, antiviral therapies, and viral evolution, chronic disease remains a major global health challenge. Long COVID is characterized by heterogeneous multisystem manifestations involving neurological, cardiovascular, pulmonary, immunological, autonomic, gastrointestinal, renal, musculoskeletal, and metabolic systems.

A central unresolved question is whether persistent SARS-CoV-2 infection contributes directly to chronic disease. Increasing evidence suggests that viral RNA, viral proteins, and replication-competent viral material may persist in selected anatomical reservoirs, including gastrointestinal tissue, lymphoid structures, central nervous system compartments, bone marrow-associated immune niches, and other tissues. These reservoirs may provide continuous antigenic stimulation, resulting in chronic immune activation, endothelial dysfunction, altered coagulation, metabolic impairment, and tissue-specific injury.

Objectives

This review examines current evidence regarding persistent SARS-CoV-2 reservoirs and their potential role in Long COVID pathogenesis. We discuss:

viral persistence mechanisms;
tissue-specific reservoirs;
molecular and genomic features;
host immune responses;
clinical phenotypes associated with persistence;
diagnostic approaches;
emerging therapeutic strategies.

Findings

Current evidence indicates that SARS-CoV-2 persistence is biologically plausible and supported by detection of viral RNA, antigen, and immune responses directed against persistent viral material in multiple tissues. The gastrointestinal tract represents one of the strongest-supported reservoirs, with prolonged detection of viral nucleic acids and proteins after acute infection. The lymphatic system may serve as a reservoir through persistent antigen presentation and immune-cell dysfunction. Neurological persistence remains an active area of investigation, with evidence suggesting possible involvement of viral components, neuroinflammation, microvascular injury, and immune-mediated neuronal dysfunction. Bone marrow and hematopoietic compartments are increasingly recognized as potential sites of long-term immune alteration.

However, persistence alone is unlikely to explain all Long COVID manifestations. Disease likely results from interactions among viral persistence, autoimmunity, mitochondrial dysfunction, endothelial injury, microbiome disruption, coagulation abnormalities, and altered host repair mechanisms.

Interpretation

Long COVID should be considered a complex biological syndrome rather than a single disease entity. Persistent SARS-CoV-2 reservoirs represent one potential mechanistic driver and provide a rationale for targeted therapeutic approaches, including antiviral strategies, immune modulation, restoration of immune homeostasis, and individualized treatment based on biological phenotype.

1. Introduction

The emergence of SARS-CoV-2 in late 2019 initiated one of the most significant global health events of the modern era. While the initial clinical focus centered on acute viral pneumonia, respiratory failure, and mortality, it rapidly became apparent that recovery from acute infection did not represent resolution of disease for a significant subset of patients.

Millions of individuals worldwide have developed prolonged symptoms following SARS-CoV-2 infection, including profound fatigue, cognitive impairment, autonomic dysfunction, exercise intolerance, dyspnea, neuropathy, cardiovascular abnormalities, gastrointestinal disturbances, sleep disorders, and immune abnormalities. These persistent manifestations have become collectively recognized as Long COVID or post-acute sequelae of SARS-CoV-2 infection.

Unlike traditional post-infectious syndromes, Long COVID frequently demonstrates objective abnormalities across multiple biological systems. Studies have identified altered immune-cell populations, persistent inflammatory signaling, endothelial dysfunction, impaired cellular metabolism, abnormal coagulation pathways, autonomic instability, and changes in tissue structure and function.

The biological basis of Long COVID remains incompletely understood. Several mechanisms have been proposed:

Persistent viral reservoirs
Immune dysregulation
Autoimmune responses
Chronic endothelial injury
Microvascular dysfunction
Mitochondrial impairment
Autonomic nervous system injury
Microbiome alterations
Epigenetic changes
Failure of normal tissue repair

Among these hypotheses, persistent viral reservoirs have attracted increasing scientific attention because they provide a potential explanation for prolonged immune activation and multisystem disease.

2. Concept of Persistent Viral Reservoirs

A viral reservoir is defined as a biological compartment in which infectious virus, viral genetic material, or viral proteins persist beyond the expected period of acute infection. Reservoirs are well established in diseases such as HIV, hepatitis B, and herpesvirus infections.

For SARS-CoV-2, the concept is more complex. Unlike HIV, SARS-CoV-2 is primarily an acute RNA virus that generally undergoes clearance. However, several observations suggest that complete elimination may not occur in all individuals.

Evidence supporting possible SARS-CoV-2 persistence includes:

prolonged detection of viral RNA after acute illness;
persistence of viral antigen in tissues;
immune responses directed against viral proteins months after infection;
detection of viral genetic material in gastrointestinal biopsies;
molecular evidence of viral evolution within individuals;
recurrence of symptoms after periods of improvement.

The clinical significance of these reservoirs remains under investigation. Persistent viral material may contribute through several mechanisms:

2.1 Chronic antigen stimulation

Continuous exposure to viral proteins may maintain activation of:

T lymphocytes;
B lymphocytes;
macrophages;
innate immune pathways.

This chronic stimulation may result in inflammatory cytokine production and immune exhaustion.

2.2 Tissue-specific inflammation

Different reservoirs may produce different clinical manifestations:

gastrointestinal persistence → dysbiosis, intestinal inflammation;
neural persistence → cognitive dysfunction and neuroinflammation;
vascular persistence → endothelial injury;
immune-cell persistence → systemic inflammatory activation.

2.3 Molecular mimicry and autoimmunity

Persistent viral antigen exposure may increase the probability of autoimmune phenomena through:

cross-reactive antibodies;
autoreactive T-cell activation;
impaired immune tolerance.

3.1 Viral genomic architecture and persistence potential

SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus belonging to the Betacoronavirus genus. Its approximately 30 kilobase genome is among the largest known RNA virus genomes and encodes both structural and non-structural proteins required for viral replication, immune evasion, and host-cell interaction.

The viral genome contains:

ORF1a and ORF1b, encoding the replication-transcription complex;
Spike (S) protein, responsible for host-cell entry;
Envelope (E), membrane (M), and nucleocapsid (N) proteins;
accessory proteins involved in immune modulation.

The spike protein interacts primarily with the host receptor angiotensin-converting enzyme 2 (ACE2), although additional host factors—including neuropilin-1, heparan sulfate, and proteases such as TMPRSS2 and cathepsins—also influence viral entry.

The broad tissue distribution of ACE2 and associated entry factors provides a biological explanation for multisystem infection. ACE2 expression has been demonstrated in:

intestinal epithelial cells;
endothelial cells;
renal tubular cells;
cardiac tissue;
olfactory epithelium;
immune-cell-associated niches;
selected regions of the nervous system.

This distribution creates the possibility that SARS-CoV-2 may access multiple anatomical compartments during acute infection, with persistence occurring preferentially in immune-privileged or poorly surveilled environments.

3.2 Viral evolution within persistent infections

RNA viruses typically undergo genetic variation because RNA-dependent RNA polymerases lack the proofreading accuracy of DNA polymerases. SARS-CoV-2 possesses a proofreading exonuclease (nsp14), reducing but not eliminating mutation.

In individuals with prolonged infection—particularly those with impaired immune responses—investigators have documented:

prolonged viral shedding;
accumulation of within-host mutations;
emergence of distinct viral lineages;
accelerated evolution compared with community transmission.

These observations suggest that some patients may provide environments where SARS-CoV-2 can undergo extended replication.

The biological implications include:

Adaptation to specific tissue environments Viral variants arising within tissues may acquire changes affecting:
- receptor binding;
- immune escape;
- replication efficiency.
Reduced immune recognition Persistent viral populations may accumulate mutations allowing partial escape from:
- neutralizing antibodies;
- T-cell recognition;
- innate antiviral mechanisms.
Compartmentalization Different tissues may contain genetically distinct viral populations.

This phenomenon is well documented in chronic viral infections such as HIV and hepatitis viruses and may represent a possible mechanism in subsets of Long COVID patients.

3.3 Viral immune evasion mechanisms

SARS-CoV-2 possesses numerous mechanisms that interfere with host antiviral immunity.

Several viral proteins suppress interferon responses:

nsp1 inhibits host messenger RNA translation;
nsp6 alters intracellular membrane structures;
ORF6 interferes with nuclear transport of immune signaling molecules;
ORF3b suppresses interferon activation.

During acute infection, these mechanisms permit viral replication before immune control develops.

In persistent infection, incomplete viral clearance may result in a state of chronic immune conflict:

Persistent viral antigen → immune activation → tissue inflammation → impaired repair → further immune dysfunction

This feedback loop may contribute to the prolonged inflammatory state observed in some Long COVID patients.

4. Gastrointestinal Reservoirs

4.1 Rationale for intestinal persistence

The gastrointestinal tract represents one of the strongest-supported potential SARS-CoV-2 reservoirs.

Several observations support intestinal involvement:

high ACE2 expression in intestinal epithelial cells;
gastrointestinal symptoms during acute COVID-19;
prolonged fecal viral RNA detection;
viral antigen detection in intestinal biopsies months after infection;
association between intestinal abnormalities and systemic inflammation.

The intestine contains a highly specialized immune environment containing:

epithelial barrier cells;
macrophages;
dendritic cells;
lymphocytes;
Peyer’s patches;
extensive mucosal immune networks.

This environment provides both opportunities for viral persistence and mechanisms for chronic immune stimulation.

4.2 Evidence for intestinal viral persistence

Multiple studies have reported persistence of SARS-CoV-2 components within gastrointestinal tissue after respiratory clearance.

Findings include:

Viral RNA detection

PCR studies have demonstrated prolonged detection of SARS-CoV-2 RNA in:

stool samples;
intestinal biopsies;
gut-associated lymphoid tissue.

Importantly, detection of RNA does not always prove active replication; however, persistence of viral genetic material suggests that viral components may remain biologically relevant.

Viral antigen detection

Immunohistochemical studies have identified:

nucleocapsid protein;
spike protein fragments;

within intestinal tissues after acute infection.

Persistent antigen exposure may contribute to ongoing immune activation.

Intestinal permeability abnormalities

COVID-19 may disrupt epithelial barrier integrity through:

epithelial apoptosis;
inflammatory cytokines;
altered tight-junction proteins.

Increased intestinal permeability may allow microbial products such as lipopolysaccharide (LPS) to enter circulation, potentially amplifying systemic inflammation.

4.3 Gut microbiome disruption

The intestinal microbiome plays a critical role in:

immune regulation;
metabolism;
inflammatory control.

Studies of COVID-19 have reported:

reduced microbial diversity;
loss of beneficial organisms;
expansion of inflammatory-associated species.

Potential consequences include:

impaired immune regulation;
increased inflammation;
altered neurotransmitter metabolism;
worsening fatigue and cognitive symptoms.

The microbiome may therefore represent both:

a consequence of infection; and
a contributor to persistent disease.

4.4 Clinical implications of intestinal reservoirs

Patients with possible gastrointestinal SARS-CoV-2 persistence may present with:

chronic diarrhea;
abdominal discomfort;
nausea;
appetite changes;
altered taste and smell;
nutritional abnormalities;
systemic inflammatory symptoms.

However, gastrointestinal persistence alone is unlikely to explain the full spectrum of Long COVID. Instead, it may act as one component of a larger multisystem process.

5. Lymphatic and Lymph Node Reservoirs

5.1 Role of lymphoid tissue in viral persistence

The lymphatic system represents a critical interface between pathogens and immune surveillance.

Potential SARS-CoV-2 persistence sites include:

lymph nodes;
tonsillar tissue;
mucosal lymphoid aggregates;
spleen-associated immune compartments.

Lymphoid tissues contain:

antigen-presenting cells;
B-cell follicles;
T-cell zones;
macrophages.

Persistent antigen within these structures could produce prolonged immune activation.

5.2 Germinal center disruption

One important observation during severe COVID-19 was abnormal germinal center formation.

Germinal centers are essential for:

antibody maturation;
memory B-cell development;
durable immune protection.

COVID-19 has been associated with:

altered B-cell differentiation;
impaired antibody maturation;
prolonged immune abnormalities.

Persistent antigen exposure may contribute to continued immune remodeling after infection.

5.3 Potential consequences

Persistent lymphoid antigen stimulation may contribute to:

chronic inflammation;
abnormal antibody production;
autoantibody generation;
immune exhaustion.

This mechanism may help explain why some patients experience:

fluctuating symptoms;
relapsing-remitting disease;
prolonged inflammatory states.

6.1 Introduction: the neurological dimension of Long COVID

Neurological symptoms represent one of the most frequent and disabling manifestations of Long COVID. Patients commonly report:

cognitive impairment (“brain fog”);
impaired attention and executive function;
memory dysfunction;
headaches;
dizziness;
sleep disruption;
sensory abnormalities;
neuropathic pain;
autonomic dysfunction;
altered smell and taste;
mood disturbances.

Objective investigations have demonstrated abnormalities in subsets of patients, including:

altered cerebral blood flow;
neuroinflammatory markers;
changes in functional brain connectivity;
autonomic nervous system dysfunction;
abnormal cerebrospinal fluid immune profiles;
evidence of endothelial and microvascular injury.

The central nervous system (CNS) presents unique biological challenges for viral clearance. The blood–brain barrier (BBB), specialized immune environment, and relative immune privilege of neural tissues can allow pathogens or pathogen-derived molecules to persist longer than in peripheral organs.

6.2 Potential routes of SARS-CoV-2 access to the nervous system

Several pathways have been proposed by which SARS-CoV-2 components may influence the CNS.

Olfactory pathway

Early COVID-19 frequently produced:

anosmia;
hyposmia;
altered smell perception.

The olfactory epithelium contains ACE2-expressing supporting cells, and the olfactory nerve provides a potential anatomical route between the nasal cavity and central nervous system.

Although direct widespread neuronal infection remains controversial, olfactory involvement demonstrates that SARS-CoV-2 can interact with tissues adjacent to the nervous system.

Hematogenous dissemination

The virus or viral components may enter the CNS through the bloodstream.

Potential mechanisms include:

endothelial infection;
disruption of the BBB;
migration within infected immune cells;
transport of viral proteins or inflammatory mediators.

The cerebral microvasculature is particularly important because endothelial cells regulate:

oxygen delivery;
immune trafficking;
vascular tone;
inflammatory signaling.

Immune-mediated CNS injury

Even without direct viral replication in neurons, SARS-CoV-2 may affect the brain through immune mechanisms.

Potential pathways include:

cytokine-mediated injury;
microglial activation;
autoantibody formation;
complement activation;
chronic interferon signaling.

6.3 Evidence for CNS viral persistence

The evidence for SARS-CoV-2 persistence in the brain is complex and remains an active area of research.

Studies have reported detection of:

viral RNA;
viral proteins;
immune responses directed against viral antigens;

in selected neurological tissues and cerebrospinal fluid samples.

However, several important distinctions must be made:

Detection of viral RNA does not necessarily indicate active replication.
Viral protein persistence may occur after infectious virus clearance.
CNS disease may result from immune activation rather than direct infection.

Current evidence supports the possibility that viral components may persist in selected individuals, but the frequency and clinical significance remain under investigation.

6.4 Neuroinflammation as a driver of cognitive dysfunction

Microglia are the resident immune cells of the CNS and function as:

immune surveillance cells;
regulators of synaptic function;
mediators of inflammatory responses.

Persistent activation of microglia may produce:

altered neuronal signaling;
impaired synaptic plasticity;
oxidative stress;
metabolic dysfunction.

This provides a plausible mechanism for:

reduced processing speed;
impaired working memory;
difficulty concentrating;
cognitive fatigue.

6.5 Cerebral microvascular dysfunction

Increasing evidence suggests that vascular dysfunction may contribute substantially to neurological Long COVID.

Potential mechanisms include:

endothelial inflammation;
impaired nitric oxide signaling;
platelet activation;
abnormal coagulation;
reduced capillary perfusion.

The brain has exceptionally high metabolic requirements. Even subtle reductions in microvascular efficiency may produce:

cognitive slowing;
fatigue;
exercise intolerance.

6.6 Autonomic nervous system involvement

A significant proportion of Long COVID patients develop symptoms consistent with autonomic dysfunction:

orthostatic intolerance;
postural tachycardia;
blood pressure instability;
abnormal sweating;
temperature dysregulation;
gastrointestinal motility abnormalities.

Potential mechanisms include:

direct or indirect injury to autonomic pathways;
autoantibodies against adrenergic or muscarinic receptors;
vascular dysfunction;
persistent immune activation.

The autonomic nervous system provides an important bridge between neurological and systemic disease.

7. Bone Marrow and Hematopoietic Reservoirs

7.1 The bone marrow as an immune-regulatory organ

Bone marrow is not simply a blood-cell production site. It is an immunologically active organ containing:

hematopoietic stem cells;
progenitor cells;
immune memory populations;
stromal cells;
cytokine-producing niches.

Because immune memory is generated and maintained within marrow compartments, persistent antigen exposure could have long-term consequences.

7.2 Evidence of hematologic abnormalities after COVID-19

Long COVID studies have identified persistent abnormalities involving:

monocyte activation;
T-cell exhaustion;
altered B-cell populations;
inflammatory signaling;
platelet activation.

Some patients demonstrate a prolonged state resembling chronic immune stimulation.

7.3 Bone marrow immune imprinting

One emerging hypothesis is that SARS-CoV-2 infection may produce long-lasting “immune imprinting.”

Possible mechanisms:

Acute infection alters hematopoietic stem-cell programming.
Epigenetic changes persist after viral clearance.
Newly generated immune cells inherit altered inflammatory responses.

This mechanism has precedent in other infections where immune responses become permanently reprogrammed.

7.4 Relationship to fatigue and metabolic dysfunction

Bone marrow abnormalities may contribute indirectly to Long COVID symptoms through:

altered oxygen transport;
persistent inflammation;
abnormal immune activation;
impaired tissue repair.

Fatigue in Long COVID is likely multifactorial, involving:

mitochondrial dysfunction;
vascular abnormalities;
autonomic impairment;
inflammatory signaling.

8. Other Potential Tissue Reservoirs

8.1 Cardiovascular tissues

The cardiovascular system is frequently affected after COVID-19.

Reported abnormalities include:

endothelial dysfunction;
myocarditis-like inflammation;
impaired exercise capacity;
autonomic cardiovascular instability.

Potential mechanisms include:

persistent antigen exposure;
immune-mediated injury;
microvascular dysfunction.

8.2 Kidney

The kidney expresses ACE2 and may be affected during and after SARS-CoV-2 infection.

Post-COVID kidney abnormalities may involve:

acute kidney injury transitioning to chronic impairment;
endothelial injury;
inflammatory damage;
microvascular dysfunction.

Patients with pre-existing renal disease may represent a particularly vulnerable population.

8.3 Skeletal muscle

Persistent muscle symptoms may involve:

mitochondrial impairment;
inflammatory infiltration;
impaired oxygen utilization;
abnormal metabolic switching.

Exercise studies have demonstrated abnormalities in subsets of patients, suggesting that symptoms may reflect physiological limitations rather than deconditioning alone.

8.4 Adipose tissue

Adipose tissue has been proposed as a possible reservoir because:

adipocytes express ACE2;
adipose tissue contains immune cells;
inflammation within fat depots can affect systemic metabolism.

Persistent inflammatory signaling from adipose tissue may contribute to metabolic abnormalities.

9. Integrative Model of Long COVID Pathogenesis

Current evidence supports a multi-hit model:

Initial SARS-CoV-2 infection

↓

Tissue dissemination and possible persistence

↓

Residual viral antigen / immune activation

↓

Chronic inflammation

↓

Endothelial injury + immune dysfunction + metabolic impairment

↓

Multisystem clinical disease

This model explains why Long COVID varies substantially between individuals.

One patient may have predominant:

neurological disease;

another:

autonomic dysfunction;

another:

vascular and cardiopulmonary symptoms.

The biological phenotype likely depends on:

host genetics;
immune status;
viral strain;
infection severity;
tissue distribution;
comorbid conditions.

10.1 Introduction: toward a molecular definition of Long COVID

A central challenge in Long COVID research has been the absence of a single definitive diagnostic marker. Unlike many infectious diseases where pathogen detection confirms diagnosis, Long COVID is a syndrome defined by persistent symptoms, functional impairment, and increasingly recognized biological abnormalities.

The heterogeneity of Long COVID suggests that multiple molecular pathways may converge to produce overlapping clinical phenotypes. Modern systems biology approaches—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, and single-cell analysis—are increasingly being applied to identify biological signatures associated with disease persistence.

The ultimate goal is to transition Long COVID from a symptom-based diagnosis toward a molecularly defined disease classification capable of:

confirming diagnosis;
identifying biological subtypes;
predicting prognosis;
selecting targeted therapies;
monitoring treatment response.

10.2 Host genetic susceptibility

10.2.1 Genetic contribution to Long COVID risk

The observation that only a subset of SARS-CoV-2-infected individuals develop prolonged illness suggests that host susceptibility factors influence disease trajectory.

Potential genetic contributors include variants affecting:

antiviral immunity;
inflammatory regulation;
coagulation pathways;
endothelial function;
mitochondrial metabolism;
autoimmune susceptibility.

Genome-wide association studies (GWAS) have identified genetic regions associated with severe COVID-19 and susceptibility to infection. Whether these same variants influence Long COVID remains an active area of investigation.

10.2.2 Immune-related genetic pathways

Genes involved in innate and adaptive immunity may influence viral clearance.

Potential pathways include:

Interferon signaling

Type I interferon responses are among the earliest antiviral defenses.

Genetic abnormalities affecting interferon pathways have been associated with:

impaired viral control;
prolonged inflammation;
severe acute disease.

A delayed or inadequate antiviral response may allow greater viral dissemination and increase the probability of persistent antigen exposure.

Human leukocyte antigen (HLA) variation

HLA molecules regulate antigen presentation to T cells.

Differences in HLA genotype influence:

which viral peptides are presented;
strength of T-cell responses;
immune memory formation.

Individuals with less effective viral antigen presentation may have increased risk of incomplete immune clearance.

10.3 Transcriptomic signatures

10.3.1 Gene expression changes in Long COVID

Transcriptomics examines patterns of messenger RNA expression across cells and tissues.

Studies of Long COVID have reported altered expression of genes involved in:

interferon signaling;
inflammatory pathways;
mitochondrial metabolism;
coagulation;
immune regulation.

These findings suggest that Long COVID may involve a persistent altered cellular state rather than simple recovery after infection.

10.3.2 Single-cell RNA sequencing

Single-cell RNA sequencing has transformed understanding of immune-cell behavior by allowing researchers to examine individual cell populations.

Reported abnormalities include:

altered monocyte activation;
dysfunctional T-cell states;
abnormal natural killer cell activity;
changes in B-cell populations.

Some studies have identified immune signatures resembling chronic viral infection, including:

persistent immune activation;
cellular exhaustion;
impaired immune regulation.

10.4 Proteomics and circulating biomarkers

Proteomics evaluates thousands of proteins simultaneously, allowing identification of molecular patterns associated with disease.

Potential Long COVID biomarkers include:

inflammatory cytokines;
complement proteins;
coagulation factors;
endothelial markers;
immune regulatory proteins.

10.4.1 Cytokine abnormalities

Persistent alterations have been reported involving:

interferons;
interleukins;
tumor necrosis factor pathways;
chemokines.

Chronic cytokine signaling may contribute to:

fatigue;
muscle symptoms;
cognitive impairment;
vascular abnormalities.

However, cytokine findings vary substantially between studies, suggesting that Long COVID consists of biologically distinct subgroups.

10.4.2 Coagulation and endothelial biomarkers

The vascular hypothesis of Long COVID has generated considerable interest.

Potential biomarkers include:

elevated von Willebrand factor;
platelet activation markers;
fibrin-related abnormalities;
endothelial adhesion molecules.

The proposed mechanism is:

Persistent inflammatory signaling

↓

Endothelial activation

↓

Abnormal coagulation regulation

↓

Microvascular dysfunction

↓

Reduced tissue oxygen delivery

↓

Fatigue, cognitive dysfunction, exercise intolerance

The degree to which these abnormalities represent primary disease drivers versus downstream consequences remains under investigation.

10.5 Metabolomics and mitochondrial dysfunction

10.5.1 Cellular energy abnormalities

Metabolomics studies examine small molecules produced during cellular metabolism.

Several studies have identified abnormalities involving:

glycolysis;
fatty-acid metabolism;
amino acid pathways;
oxidative phosphorylation.

These findings are particularly relevant because many Long COVID patients experience:

post-exertional malaise;
reduced exercise capacity;
profound fatigue.

10.5.2 Mitochondrial dysfunction hypothesis

Mitochondria regulate:

ATP production;
reactive oxygen species;
cellular stress responses;
immune metabolism.

Potential mechanisms include:

inflammatory disruption of mitochondrial function;
viral interference with cellular metabolism;
oxidative stress;
impaired mitochondrial repair.

A mitochondrial contribution could explain why some patients experience disproportionate symptoms despite normal conventional testing.

10.6 Autoimmune signatures

10.6.1 Autoantibody generation

Multiple studies have reported increased autoantibodies after SARS-CoV-2 infection.

Potential targets include:

nuclear antigens;
phospholipids;
endothelial proteins;
autonomic receptors.

Autoimmune mechanisms could contribute to:

dysautonomia;
neuropathy;
vascular dysfunction;
inflammatory symptoms.

10.6.2 Molecular mimicry

Molecular mimicry occurs when immune responses against viral proteins cross-react with human proteins.

Potential consequences include:

persistent immune activation;
tissue injury;
impaired recovery.

However, the presence of autoantibodies does not always establish causation; some may represent biomarkers rather than direct pathogenic agents.

10.7 Microbiome genomics

The gut microbiome represents a major interface between viral persistence and systemic immunity.

Metagenomic studies have identified changes involving:

reduced microbial diversity;
loss of beneficial organisms;
expansion of inflammatory-associated species.

Potential mechanisms:

SARS-CoV-2 infection alters intestinal ecology.
Microbial imbalance increases intestinal permeability.
Microbial products enter circulation.
Systemic immune activation increases.

This gut–immune axis may contribute to multisystem symptoms.

10.8 Development of diagnostic biomarkers

An ideal Long COVID biomarker would:

distinguish affected patients from recovered controls;
identify biological subtype;
correlate with disease severity;
respond to treatment.

Potential future diagnostic panels may combine:

viral antigen detection;
immune profiling;
inflammatory markers;
metabolomic signatures;
imaging findings;
physiologic measurements.

A single marker is unlikely to capture the complexity of Long COVID.

10.9 Precision medicine framework

The future of Long COVID care will likely require biological classification.

Potential patient categories may include:

Viral persistence phenotype

Characteristics:

persistent viral antigen;
immune activation;
possible tissue reservoirs.

Potential therapies:

antiviral strategies;
immune enhancement.

Immune dysregulation phenotype

Characteristics:

abnormal cytokines;
autoantibodies;
inflammatory signatures.

Potential therapies:

immunomodulation;
targeted anti-inflammatory approaches.

Vascular phenotype

Characteristics:

endothelial dysfunction;
coagulation abnormalities;
impaired microcirculation.

Potential therapies:

vascular protective strategies;
individualized antithrombotic approaches under clinical supervision.

Autonomic phenotype

Characteristics:

orthostatic intolerance;
abnormal heart-rate regulation;
autonomic symptoms.

Potential therapies:

autonomic rehabilitation;
volume management;
targeted pharmacologic therapy.

Metabolic phenotype

Characteristics:

mitochondrial dysfunction;
impaired energy metabolism.

Potential therapies:

metabolic rehabilitation;
targeted mitochondrial support strategies.

11. Clinical Manifestations of Persistent SARS-CoV-2 Infection

Long COVID represents one of the most heterogeneous post-infectious conditions described in modern medicine. Symptoms may begin immediately after acute infection or emerge after a period of apparent recovery.

Common clinical domains include:

neurological;
cardiovascular;
pulmonary;
autonomic;
gastrointestinal;
renal;
musculoskeletal;
immunological;
dermatological;
reproductive.

The following section will provide a detailed clinical review of each organ system, mechanisms linking persistent viral reservoirs to symptoms, and implications for diagnosis and treatment.

11.1 Introduction: Long COVID as a multisystem disease

Long COVID, also termed post-acute sequelae of SARS-CoV-2 infection (PASC), is characterized by persistent or recurrent symptoms following acute SARS-CoV-2 infection. Although definitions vary among international organizations, most clinical criteria recognize symptoms lasting at least several weeks to months after infection and not explained by an alternative diagnosis.

Unlike uncomplicated recovery from an acute viral illness, Long COVID frequently demonstrates:

prolonged functional impairment;
objective physiological abnormalities;
fluctuating disease activity;
relapsing-remitting patterns;
involvement of multiple organ systems.

The diversity of clinical manifestations reflects the broad tissue distribution of SARS-CoV-2 entry factors, the complexity of host immune responses, and the possibility of persistent viral components in selected tissues.

11.2 Neurological manifestations

Neurological disease represents one of the most commonly reported and disabling components of Long COVID.

11.2.1 Cognitive dysfunction (“brain fog”)

Cognitive impairment is among the most characteristic symptoms.

Patients commonly describe:

difficulty concentrating;
impaired short-term memory;
slowed information processing;
word-finding difficulty;
reduced executive function;
mental fatigue.

Neuropsychological testing has demonstrated abnormalities in subsets of patients, particularly involving:

attention;
processing speed;
working memory;
executive function.

Potential mechanisms include:

Neuroinflammation

Persistent activation of microglia and astrocytes may alter neuronal signaling.

Cerebrovascular dysfunction

Reduced cerebral blood flow and endothelial injury may impair oxygen delivery.

Immune-mediated neuronal dysfunction

Autoantibodies and inflammatory mediators may interfere with normal neural communication.

Metabolic impairment

Reduced mitochondrial efficiency may limit neuronal energy production.

11.2.2 Peripheral neuropathy

Many Long COVID patients report:

numbness;
burning pain;
tingling;
altered temperature sensation;
hypersensitivity;
abnormal skin sensations.

Small-fiber neuropathy has received particular attention.

Small fibers regulate:

pain perception;
temperature sensation;
autonomic function.

Potential mechanisms include:

immune-mediated nerve injury;
vascular compromise;
inflammatory damage;
autoimmune attack against neuronal structures.

Skin biopsy studies in selected patients have demonstrated reduced intraepidermal nerve fiber density, supporting objective peripheral nerve involvement.

11.2.3 Vestibular and sensory dysfunction

Patients may experience:

dizziness;
imbalance;
vertigo;
tinnitus;
hearing changes;
altered spatial orientation.

Potential contributors include:

autonomic dysfunction;
inner ear inflammation;
microvascular injury;
central sensory processing abnormalities.

11.3 Dysautonomia and autonomic dysfunction

11.3.1 Clinical presentation

Autonomic dysfunction has emerged as a major Long COVID phenotype.

Symptoms include:

rapid heart rate after standing;
lightheadedness;
blood pressure instability;
exercise intolerance;
temperature regulation problems;
abnormal sweating;
gastrointestinal motility disturbances.

A common presentation resembles:

postural orthostatic tachycardia syndrome (POTS);
orthostatic intolerance;
autonomic neuropathy.

11.3.2 Pathophysiology

Potential mechanisms include:

Autoimmune autonomic injury

Antibodies against:

adrenergic receptors;
muscarinic receptors;

may alter autonomic signaling.

Vascular dysfunction

Impaired vascular constriction may cause excessive pooling of blood in dependent tissues.

Neuropathy

Damage to small autonomic fibers may impair regulation of:

heart rate;
blood pressure;
gastrointestinal function.

Persistent inflammation

Chronic immune activation may interfere with autonomic regulation.

11.4 Cardiovascular manifestations

11.4.1 Spectrum of disease

Cardiovascular manifestations range from mild abnormalities to severe disease.

Reported findings include:

tachycardia;
palpitations;
chest discomfort;
exercise intolerance;
abnormal blood pressure regulation;
myocarditis-like syndromes.

11.4.2 Endothelial dysfunction

The vascular endothelium regulates:

blood flow;
inflammation;
coagulation;
vascular repair.

SARS-CoV-2 infection may impair endothelial function through:

inflammatory activation;
oxidative stress;
immune-mediated injury.

Potential consequences:

impaired microcirculation;
abnormal tissue oxygen delivery;
increased vascular inflammation.

11.4.3 Exercise intolerance

Many Long COVID patients demonstrate reduced exercise capacity.

Potential mechanisms include:

impaired oxygen extraction;
mitochondrial dysfunction;
autonomic abnormalities;
abnormal skeletal muscle metabolism.

Cardiopulmonary exercise testing (CPET) studies have demonstrated physiological abnormalities in subsets of patients, including:

reduced peak oxygen consumption;
abnormal ventilatory responses;
impaired oxygen utilization.

11.5 Pulmonary manifestations

Although many patients recover normal lung imaging after acute COVID-19, others develop persistent respiratory symptoms.

Common complaints:

shortness of breath;
chest tightness;
cough;
reduced exercise tolerance.

Potential mechanisms:

residual inflammation;
small airway disease;
vascular abnormalities;
impaired diffusion capacity.

11.5.1 Pulmonary vascular injury

COVID-19 has a strong association with endothelial injury and thrombovascular abnormalities.

Persistent vascular dysfunction may contribute to:

exertional dyspnea;
impaired oxygen transfer;
fatigue.

11.6 Gastrointestinal manifestations

The gastrointestinal tract is important because it represents:

a potential viral reservoir;
a major immune organ;
a regulator of systemic inflammation.

Symptoms include:

diarrhea;
abdominal pain;
nausea;
reflux;
appetite disturbance;
altered bowel habits.

11.6.1 Gut–immune axis

Persistent intestinal abnormalities may contribute through:

altered microbiome composition;
increased intestinal permeability;
immune activation.

The intestine contains approximately 70% of the body’s immune tissue, making prolonged intestinal inflammation potentially relevant to systemic disease.

11.7 Renal manifestations

COVID-19 has been associated with both acute and chronic kidney injury.

Potential mechanisms:

direct viral effects;
endothelial injury;
inflammatory damage;
microvascular dysfunction.

Post-COVID kidney abnormalities may include:

reduced estimated glomerular filtration rate;
persistent proteinuria;
accelerated chronic kidney disease progression in susceptible individuals.

Patients with pre-existing kidney disease may have increased vulnerability.

11.8 Hematological abnormalities

Long COVID studies have identified abnormalities involving:

inflammatory markers;
platelet activation;
coagulation pathways;
immune-cell populations.

Potential mechanisms:

persistent immune activation;
endothelial dysfunction;
altered fibrinolysis.

The clinical significance of circulating microclot-like structures remains under active investigation. While some studies report increased fibrin-related abnormalities in Long COVID, standardized diagnostic methods and consensus clinical interpretation have not yet been established.

11.9 Musculoskeletal manifestations

Common symptoms:

muscle pain;
weakness;
reduced endurance;
joint discomfort;
post-exertional worsening.

Potential contributors:

mitochondrial dysfunction;
inflammatory signaling;
impaired muscle metabolism;
altered autonomic regulation.

11.10 Dermatologic and sensory manifestations

Reported findings include:

hair shedding;
rashes;
temperature sensitivity;
abnormal skin sensations;
itching.

Mechanisms may include:

immune activation;
vascular changes;
nerve dysfunction.

11.11 Post-exertional symptom exacerbation

One of the most clinically important features is worsening after physical, cognitive, or emotional exertion.

Symptoms may include:

profound fatigue;
pain;
cognitive worsening;
autonomic instability.

The biological basis may involve:

impaired energy metabolism;
inflammatory activation;
abnormal recovery pathways.

This feature differentiates many Long COVID patients from simple deconditioning.

11.12 Clinical spectrum and severity

Long COVID exists across a broad spectrum.

Mild disease

intermittent fatigue;
mild cognitive symptoms;
reduced exercise tolerance.

Moderate disease

persistent neurological symptoms;
autonomic dysfunction;
significant activity limitation.

Severe disease

inability to work;
mobility impairment;
multisystem organ dysfunction;
profound disability.

The severity does not always correlate with the severity of the initial acute infection. Individuals with mild acute COVID-19 may develop severe persistent illness.

11.13 Clinical implications

The recognition of Long COVID as a multisystem disorder requires:

multidisciplinary evaluation;
individualized treatment;
objective assessment of organ involvement;
attention to biological subtype.

A purely symptom-based approach is insufficient because the underlying mechanisms differ among patients.

12.1 Introduction: the challenge of diagnosing Long COVID

One of the greatest challenges in Long COVID medicine has been the absence of a single definitive diagnostic test. The condition is not defined by one organ abnormality or one measurable laboratory abnormality. Instead, diagnosis requires integration of:

clinical history;
symptom pattern;
functional impairment;
laboratory evaluation;
physiological testing;
imaging;
emerging molecular biomarkers.

The complexity of Long COVID reflects its probable biological heterogeneity. Two patients with identical symptoms may have different underlying mechanisms:

one may have persistent viral antigen;
another may have autoimmune activation;
another may have autonomic dysfunction;
another may have vascular or metabolic impairment.

Therefore, future diagnostic strategies will likely require biological phenotyping rather than a single universal test.

12.2 Clinical diagnostic framework

12.2.1 Comprehensive clinical history

The initial evaluation should characterize:

timing of acute infection;
severity of initial illness;
vaccination status;
prior infections;
symptom onset pattern;
progression or relapse;
functional limitations;
exertional response.

Important clinical questions include:

Did symptoms begin after SARS-CoV-2 infection?
Are symptoms persistent, fluctuating, or progressive?
Is there delayed worsening after activity?
Are multiple organ systems involved?

12.2.2 Symptom domain assessment

A systematic evaluation should assess:

Neurological

cognition;
memory;
headaches;
neuropathy;
balance;
sleep.

Cardiovascular/autonomic

heart rate response;
orthostatic symptoms;
blood pressure changes;
palpitations.

Pulmonary

dyspnea;
cough;
oxygen limitation.

Gastrointestinal

bowel changes;
abdominal symptoms;
nutritional status.

Renal/metabolic

kidney function;
glucose abnormalities;
electrolyte disturbances.

12.3 Laboratory evaluation

Routine laboratory testing is frequently normal in Long COVID; however, abnormalities may identify specific biological pathways.

Commonly evaluated markers include:

Inflammation

C-reactive protein (CRP);
erythrocyte sedimentation rate (ESR);
ferritin;
inflammatory cytokines when available.

Hematology

complete blood count;
platelet count;
red blood cell indices.

Coagulation

D-dimer;
fibrinogen;
coagulation studies.

Metabolic function

comprehensive metabolic panel;
glucose;
thyroid studies;
nutritional markers.

12.4 Biomarkers associated with persistent disease

12.4.1 Viral antigen detection

One area of active investigation is detection of persistent SARS-CoV-2 antigen.

Potential sources include:

plasma;
immune cells;
tissue samples.

Persistent antigen may indicate:

ongoing viral activity;
residual viral fragments;
prolonged immune stimulation.

However, important limitations exist:

assays are not yet standardized;
sensitivity varies;
presence of antigen does not always prove active infection.

12.4.2 Immune biomarkers

Potential immune signatures include:

altered T-cell populations;
abnormal B-cell maturation;
elevated inflammatory cytokines;
persistent interferon signaling.

These findings support the concept that Long COVID involves prolonged immune remodeling.

12.4.3 Autoimmune markers

Investigational studies have identified:

antinuclear antibodies;
antiphospholipid antibodies;
receptor-directed antibodies.

Potential targets include:

autonomic receptors;
endothelial structures;
neural proteins.

The clinical role of routine autoimmune testing remains uncertain because many antibodies may be nonspecific.

12.5 Imaging approaches

12.5.1 Brain imaging

Conventional MRI is often normal; however, advanced techniques have identified abnormalities in subsets of patients.

Investigational findings include:

altered functional connectivity;
changes in cerebral blood flow;
neuroinflammatory signatures.

Potential imaging modalities:

functional MRI;
PET imaging;
advanced perfusion studies.

12.5.2 Cardiac imaging

Evaluation may include:

echocardiography;
cardiac MRI;
rhythm monitoring.

Potential abnormalities:

impaired ventricular function;
inflammation;
abnormal strain patterns.

12.5.3 Pulmonary imaging

Assessment may include:

chest CT;
pulmonary function testing.

Findings may include:

residual inflammatory changes;
small airway abnormalities;
diffusion impairment.

12.6 Autonomic testing

Because dysautonomia is a major Long COVID phenotype, specialized testing can be valuable.

Tilt-table testing

Assesses:

heart rate response;
blood pressure regulation;
orthostatic intolerance.

Heart-rate variability analysis

Heart-rate variability (HRV) reflects autonomic balance.

Alterations may indicate:

impaired parasympathetic activity;
excessive sympathetic activation.

Machine-learning approaches using HRV patterns are being investigated as potential diagnostic tools.

12.7 Cardiopulmonary exercise testing (CPET)

CPET provides one of the most detailed assessments of exercise physiology.

Measured parameters include:

oxygen consumption (VO₂);
carbon dioxide production;
ventilatory efficiency;
anaerobic threshold.

Long COVID studies have identified abnormalities such as:

reduced peak VO₂;
impaired oxygen extraction;
abnormal ventilatory responses.

These findings suggest physiological impairment beyond simple inactivity.

12.8 Neurological assessment

Evaluation may include:

cognitive testing;
nerve conduction studies;
skin biopsy for small-fiber neuropathy;
autonomic nerve testing;
vestibular evaluation.

Potential abnormalities:

reduced small-fiber density;
abnormal sensory processing;
autonomic impairment.

12.9 Gastrointestinal evaluation

Patients with suspected intestinal involvement may undergo:

stool inflammatory markers;
microbiome analysis;
endoscopy when clinically indicated.

Research approaches include:

intestinal biopsy;
viral antigen detection;
immune profiling.

12.10 Kidney assessment

Because SARS-CoV-2 affects vascular and renal systems, evaluation may include:

serum creatinine;
estimated glomerular filtration rate (eGFR);
urine protein assessment;
electrolyte monitoring.

Persistent kidney abnormalities may represent:

unresolved inflammation;
vascular injury;
progression of underlying renal disease.

12.11 Emerging multi-omic diagnostic platforms

The future of Long COVID diagnosis will likely involve integrated biological analysis.

Potential combined platforms include:

Proteomics

Identifies abnormal protein patterns.

Transcriptomics

Measures gene-expression changes.

Metabolomics

Identifies altered cellular metabolism.

Immunomics

Maps immune-cell behavior.

Viral genomics

Detects persistent viral evolution or genetic material.

A combined molecular signature may eventually allow:

objective diagnosis;
disease classification;
treatment matching.

12.12 Limitations of current diagnostics

Important limitations remain:

No universally accepted biomarker exists.
Many abnormalities overlap with other inflammatory disorders.
Different studies identify different biological signatures.
Tissue reservoirs are difficult to sample.
Some mechanisms may coexist in the same patient.

Therefore, diagnosis currently remains clinical, supported by objective findings where available.

12.13 Future diagnostic model

The likely future approach is:

Clinical phenotype

Immune profile

Metabolic profile

Vascular assessment

Viral persistence assessment

Personalized Long COVID classification

This approach parallels modern oncology and autoimmune medicine, where treatment decisions increasingly depend on biological subtype rather than symptoms alone.

13.1 Introduction: from symptom management to mechanism-based treatment

The therapeutic landscape of Long COVID remains one of the most rapidly evolving areas in medicine. Early clinical approaches focused primarily on supportive care and rehabilitation because the biological basis of persistent disease was uncertain. As evidence has accumulated regarding persistent viral components, immune dysregulation, endothelial dysfunction, autonomic abnormalities, and metabolic impairment, therapeutic strategies are increasingly shifting toward mechanism-based interventions.

Long COVID is unlikely to respond to a single universal therapy because the disease represents a convergence of multiple biological pathways.

A future therapeutic model will likely involve:

Biological phenotype identification

↓

Mechanism-directed therapy

↓

Objective monitoring of response

Potential therapeutic categories include:

antiviral approaches;
immune modulation;
anti-inflammatory therapy;
vascular and endothelial protection;
autonomic stabilization;
metabolic and mitochondrial support;
rehabilitation strategies;
regenerative and precision medicine approaches.

13.2 Antiviral strategies targeting persistent SARS-CoV-2 reservoirs

13.2.1 Rationale for antiviral therapy

If persistent viral reservoirs contribute to Long COVID, antiviral therapy represents a logical therapeutic strategy.

The theoretical mechanism:

Persistent viral reservoir

↓

Continued antigen release

↓

Chronic immune activation

↓

Tissue dysfunction

↓

Symptoms

Reducing viral burden could theoretically interrupt this cycle.

13.2.2 Nucleoside analogue antivirals

Several antiviral agents inhibit SARS-CoV-2 replication by interfering with viral RNA synthesis.

Examples include:

remdesivir;
nirmatrelvir/ritonavir.

The strongest evidence for these agents remains in acute COVID-19, particularly among high-risk patients early in infection.

Whether antiviral treatment benefits established Long COVID remains uncertain.

13.2.3 Paxlovid and Long COVID investigation

Nirmatrelvir/ritonavir has generated considerable interest because of its ability to inhibit the SARS-CoV-2 main protease.

The theoretical benefits include:

suppression of residual replication;
reduction of antigen production;
decreased immune stimulation.

Observational studies have produced mixed findings:

Some suggest:

reduced risk of Long COVID when given during acute infection.

Others show:

limited benefit once chronic symptoms are established.

Randomized clinical trials are needed to determine:

optimal timing;
duration;
patient selection.

13.2.4 Prolonged antiviral therapy hypothesis

A major research question is whether longer antiviral courses may be required in patients with suspected reservoirs.

Potential candidates:

patients with persistent antigen;
patients with immune dysfunction;
patients with relapsing symptoms.

Challenges include:

identifying appropriate patients;
avoiding resistance;
determining treatment duration.

13.3 Immune modulation strategies

13.3.1 Rationale

Persistent immune activation is one of the most consistent findings in Long COVID research.

Potential immune abnormalities include:

chronic interferon signaling;
altered T-cell function;
abnormal B-cell responses;
inflammatory cytokine production;
autoantibody generation.

13.3.2 Corticosteroids

Although corticosteroids are highly effective in severe acute COVID-19, their role in established Long COVID is limited.

Potential concerns:

immune suppression;
worsening persistent infection;
metabolic complications.

Routine long-term corticosteroid therapy is not currently supported without a specific inflammatory indication.

13.3.3 Immunomodulatory therapies

Potential future approaches include targeted therapies affecting:

cytokine pathways;
B-cell activity;
T-cell activation;
complement activation.

Examples being investigated in immune-mediated diseases include:

JAK inhibitors;
monoclonal antibodies;
B-cell-directed therapies.

However, Long COVID-specific evidence remains limited.

13.4 Antihistamines and mast-cell-related pathways

13.4.1 Mast-cell activation hypothesis

Some Long COVID patients report symptoms resembling mast-cell activation:

flushing;
itching;
gastrointestinal symptoms;
tachycardia;
allergic-type reactions.

Mast cells regulate:

inflammation;
vascular permeability;
immune signaling.

13.4.2 H1 and H2 receptor blockade

Small observational studies have reported symptom improvement in some patients treated with:

H1 antihistamines;
H2 blockers.

Possible mechanisms:

reduction of inflammatory mediator release;
stabilization of mast-cell activity.

Large randomized trials are needed.

13.5 Low-dose naltrexone (LDN)

13.5.1 Proposed mechanism

Low-dose naltrexone has been proposed as an immune-modulating therapy through:

microglial modulation;
reduction of inflammatory signaling;
alteration of toll-like receptor pathways.

Potential targets include:

neuroinflammation;
chronic pain;
fatigue syndromes.

13.5.2 Current evidence

Evidence remains preliminary.

Small studies suggest possible improvement in:

fatigue;
pain;
cognitive symptoms.

However:

sample sizes are small;
placebo-controlled trials are limited.

13.6 Intravenous immunoglobulin (IVIG)

13.6.1 Biological rationale

IVIG has immunomodulatory properties including:

suppression of autoantibodies;
regulation of inflammatory pathways;
modulation of immune-cell activity.

It has established roles in:

autoimmune neuropathies;
inflammatory disorders.

13.6.2 Potential Long COVID applications

IVIG is being investigated particularly in patients with:

immune-mediated neuropathy;
dysautonomia;
autoimmune features.

Limitations include:

cost;
availability;
uncertain patient selection.

13.7 Vascular and microcirculatory approaches

13.7.1 Endothelial dysfunction hypothesis

Persistent endothelial abnormalities may contribute to:

fatigue;
cognitive impairment;
exercise intolerance.

Therapeutic strategies under investigation include:

endothelial-protective approaches;
management of cardiovascular risk factors;
targeted vascular therapies.

13.7.2 Anticoagulation and fibrinolytic approaches

Some researchers have proposed that abnormal fibrin formation and impaired fibrinolysis contribute to Long COVID symptoms.

Potential mechanisms:

microvascular obstruction;
impaired oxygen delivery;
inflammatory amplification.

However:

standardized diagnostic criteria are lacking;
risks of anticoagulant therapy are significant;
evidence remains insufficient for routine use.

Anticoagulation should therefore be individualized and medically supervised.

13.8 Mitochondrial and metabolic therapies

13.8.1 Rationale

Because many patients demonstrate impaired energy metabolism, therapies targeting mitochondrial function are being explored.

Potential interventions include:

graded metabolic rehabilitation;
nutritional optimization;
correction of deficiencies;
mitochondrial cofactors.

13.8.2 Metabolic targets

Areas of interest:

oxidative phosphorylation;
NAD+ metabolism;
oxidative stress pathways;
cellular energy regulation.

Clinical evidence remains preliminary.

13.9 Autonomic rehabilitation

13.9.1 Dysautonomia management

Treatment approaches include:

hydration optimization;
electrolyte management when appropriate;
compression strategies;
autonomic rehabilitation;
carefully individualized exercise approaches.

13.9.2 Exercise considerations

Traditional exercise prescriptions may worsen symptoms in patients with post-exertional malaise.

Modern approaches emphasize:

pacing;
symptom-guided activity;
gradual functional restoration.

13.10 Neurological rehabilitation

Approaches include:

cognitive rehabilitation;
sleep optimization;
occupational therapy;
symptom-specific neurological treatment.

Goals:

improve function;
compensate for cognitive deficits;
restore independence.

13.11 Vagus nerve and neuromodulation approaches

The vagus nerve regulates:

inflammation;
autonomic balance;
immune signaling.

Investigational approaches include:

non-invasive vagus nerve stimulation;
autonomic modulation therapies.

Potential mechanisms:

increased parasympathetic activity;
reduced inflammatory signaling.

13.12 Future precision therapeutics

The future of Long COVID treatment will likely resemble precision medicine.

Possible therapeutic matching:

Biological phenotype	Potential therapy
Persistent viral antigen	Antiviral strategies
Autoimmune phenotype	Immunomodulation
Dysautonomia phenotype	Autonomic therapies
Vascular phenotype	Endothelial strategies
Metabolic phenotype	Mitochondrial/metabolic approaches
Neuropathic phenotype	Neurological therapies

13.13 Current limitations

Major barriers include:

Lack of validated biomarkers.
Heterogeneous patient populations.
Limited randomized trials.
Difficulty measuring treatment response.
Multiple simultaneous mechanisms.

Future clinical trials must move beyond symptom-only outcomes and incorporate:

molecular biomarkers;
physiological measurements;
imaging;
functional outcomes.

13.14 Conclusion

The treatment of Long COVID is entering a new phase. The field is transitioning from empiric symptom management toward biologically informed intervention. Persistent viral reservoirs remain one important hypothesis among several interacting mechanisms.

The most promising future strategy is unlikely to be a single “Long COVID cure,” but rather a personalized therapeutic framework addressing the dominant biological drivers in each patient.

14. Future Directions: Research Priorities, Clinical Trials, Unanswered Questions, and the Path Toward Disease-Modifying Therapies

This final major section will address:

unresolved reservoir questions,
vaccine effects,
next-generation antivirals,
biomarker validation,
artificial intelligence,
tissue sampling,
global research priorities,
and a concluding synthesis suitable for a Lancet-style review.

14.1 Introduction: the transition from recognition to resolution

The emergence of Long COVID represents one of the most significant medical challenges following the SARS-CoV-2 pandemic. The scientific community has moved rapidly from recognizing a novel syndrome to identifying measurable biological abnormalities and developing targeted interventions.

The central challenge now is no longer whether Long COVID exists, but rather:

Which biological mechanisms dominate in individual patients?
Which patients harbor persistent viral reservoirs?
Which abnormalities are causal versus secondary?
Which therapies can produce durable recovery?

The next phase of research must transition from descriptive epidemiology toward mechanism-based precision medicine.

14.2 Defining the role of persistent viral reservoirs

14.2.1 Major unresolved questions

Although evidence supports the possibility of persistent SARS-CoV-2 components in multiple tissues, several fundamental questions remain unanswered.

Question 1: How common are reservoirs?

Important uncertainties include:

What percentage of Long COVID patients harbor persistent viral material?
Does persistence occur in recovered individuals without symptoms?
Are reservoirs more common after severe infection?
Are reservoirs associated with specific viral variants?

Question 2: Are reservoirs infectious?

A critical distinction must be made between:

persistent viral RNA;
persistent viral protein;
replication-competent virus.

Detection of viral genetic material does not necessarily indicate active viral replication.

Future studies require:

viral culture methods;
tissue-specific sequencing;
longitudinal sampling.

Question 3: Do reservoirs directly cause symptoms?

Several possibilities exist:

Model A: Direct pathogenic model

Persistent viral replication causes:

tissue injury;
inflammation;
immune activation.

Model B: Antigen persistence model

The virus is no longer actively replicating, but residual proteins continue to stimulate immunity.

Model C: Trigger model

The initial infection initiates irreversible changes:

autoimmunity;
metabolic dysfunction;
vascular injury.

The true mechanism may involve all three models.

14.3 Development of tissue-based diagnostics

A major limitation in Long COVID research is that many suspected biological abnormalities cannot be easily measured.

Future diagnostic approaches may include:

Tissue antigen mapping

Advanced methods may identify:

viral proteins;
inflammatory pathways;
immune-cell infiltration.

Spatial transcriptomics

This emerging technology allows researchers to determine:

which cells express specific genes;
where inflammatory pathways occur;
how tissues are organized during disease.

Potential applications:

intestinal biopsies;
lymphoid tissues;
brain tissue obtained through rare clinical circumstances.

Single-cell multi-omics

Combining:

gene expression;
immune receptor sequencing;
protein measurement;

may reveal patient-specific disease mechanisms.

14.4 Next-generation antiviral strategies

14.4.1 Beyond acute infection treatment

Current antiviral drugs were primarily developed to prevent severe acute COVID-19.

Future therapies may need to address:

tissue penetration;
persistent reservoirs;
immune restoration.

14.4.2 Combination antiviral therapy

Persistent infections in other diseases often require combination approaches.

Potential future strategies may include:

antiviral combinations;
antivirals plus immune modulation;
reservoir-targeting approaches.

However, these strategies require rigorous clinical trials.

14.5 Vaccine research and Long COVID

14.5.1 Prevention remains the most effective strategy

Vaccination continues to reduce:

severe acute disease;
hospitalization;
mortality.

The degree to which vaccination prevents Long COVID remains an area of ongoing research.

14.5.2 Therapeutic vaccines

Future vaccine concepts may explore:

stronger mucosal immunity;
improved tissue-level viral clearance;
broader variant protection.

Potential goals:

prevent infection;
prevent persistence;
reduce chronic antigen exposure.

14.6 Artificial intelligence and computational medicine

Artificial intelligence is increasingly being applied to Long COVID research.

Potential applications include:

Diagnostic prediction

AI models may integrate:

symptoms;
laboratory data;
imaging;
wearable-device measurements.

Biological clustering

Machine learning may identify hidden patient subgroups based on:

immune profiles;
genetics;
metabolomics.

Treatment selection

Future systems may predict:

which patients respond to antivirals;
who requires immune modulation;
who benefits from autonomic therapy.

14.7 Wearable technology and continuous monitoring

Long COVID symptoms often fluctuate.

Wearable devices may provide objective measurements of:

heart rate variability;
sleep patterns;
activity tolerance;
autonomic changes.

Potential advantages:

real-time monitoring;
detection of relapse;
measurement of treatment response.

14.8 Clinical trial priorities

Future Long COVID trials should incorporate several principles.

14.8.1 Biological enrollment criteria

Instead of enrolling patients solely by symptoms, trials should identify:

inflammatory phenotypes;
viral persistence phenotypes;
autonomic phenotypes;
metabolic phenotypes.

14.8.2 Objective endpoints

Clinical trials should measure:

exercise capacity;
cognitive testing;
inflammatory biomarkers;
autonomic function;
imaging changes.

14.8.3 Combination therapy evaluation

Because Long COVID is likely multifactorial, future trials may need to evaluate combinations such as:

antiviral + immune modulation;
vascular therapy + rehabilitation;
metabolic therapy + autonomic treatment.

14.9 Ethical and healthcare implications

Long COVID has created substantial societal consequences.

Impacts include:

disability;
workforce reduction;
healthcare burden;
reduced quality of life.

Healthcare systems must develop:

specialized clinics;
multidisciplinary care models;
physician education;
disability assessment frameworks.

14.10 Research priorities for the next decade

Major priorities include:

1. Validate biomarkers

Reliable biomarkers are essential for:

diagnosis;
prognosis;
clinical trials.

2. Identify causal mechanisms

Research must distinguish:

primary drivers;
downstream effects.

3. Develop disease-modifying therapies

The field must move beyond:

symptom management;

toward:

biological correction.

4. Establish patient subtypes

A universal treatment strategy is unlikely.

5. Understand recovery biology

Important questions:

Why do some patients recover?
Why do others remain ill?
Can recovery pathways be therapeutically enhanced?

15. Conclusions

Long COVID represents a complex multisystem disorder arising after SARS-CoV-2 infection. Current evidence supports a model in which persistent viral components, immune dysregulation, endothelial dysfunction, metabolic impairment, autonomic disturbance, and tissue-specific injury interact to produce prolonged illness.

Persistent SARS-CoV-2 reservoirs remain one of the most compelling hypotheses explaining chronic disease in a subset of patients. Evidence supporting possible persistence has emerged from investigations of:

gastrointestinal tissues;
lymphoid structures;
neurological compartments;
immune-cell-associated niches;
other organs.

However, persistence should not be considered the sole explanation for Long COVID. The disease is likely heterogeneous, with different biological pathways dominating in different individuals.

The future of Long COVID medicine will depend on:

molecular classification;
validated biomarkers;
targeted therapies;
multidisciplinary care;
rigorous clinical trials.

The scientific trajectory is moving from recognition of Long COVID as a poorly understood post-viral syndrome toward understanding it as a biologically definable disease spectrum. Continued investigation of viral reservoirs, immune regulation, and host-pathogen interactions offers the possibility of transforming Long COVID from a condition managed primarily through symptom control into one treated through mechanism-based precision medicine.

References

Foundational Long COVID Definitions and Epidemiology

1. Nalbandian A, Sehgal K, Gupta A, et al.
Post-acute COVID-19 syndrome.
Nature Medicine. 2021;27:601–615.
doi:10.1038/s41591-021-01283-z

2. Davis HE, McCorkell L, Vogel JM, Topol EJ.
Long COVID: major findings, mechanisms and recommendations.
Nature Reviews Microbiology. 2023;21:133–146.
doi:10.1038/s41579-022-00846-2

3. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV.
A clinical case definition of post-COVID-19 condition by a Delphi consensus.
Lancet Infectious Diseases. 2022;22:e102–e107.
doi:10.1016/S1473-3099(21)00703-9

4. Writing Committee for the WHO Working Group.
Post COVID-19 condition: WHO consensus definition.
Lancet Infectious Diseases. 2022.

SARS-CoV-2 Biology, Genomics, and Viral Persistence

5. V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V.
Coronavirus biology and replication: implications for SARS-CoV-2.
Nature Reviews Microbiology. 2021;19:155–170.
doi:10.1038/s41579-020-00468-6

6. Hu B, Guo H, Zhou P, Shi ZL.
Characteristics of SARS-CoV-2 and COVID-19.
Nature Reviews Microbiology. 2021;19:141–154.
doi:10.1038/s41579-020-00459-7

7. Jackson CB, Farzan M, Chen B, Choe H.
Mechanisms of SARS-CoV-2 entry into cells.
Nature Reviews Molecular Cell Biology. 2022;23:3–20.
doi:10.1038/s41580-021-00418-x

8. Zhou P, Yang XL, Wang XG, et al.
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020;579:270–273.
doi:10.1038/s41586-020-2012-7

9. Hoffmann M, Kleine-Weber H, Schroeder S, et al.
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2.
Cell. 2020;181:271–280.
doi:10.1016/j.cell.2020.02.052

Persistent Viral Reservoirs

10. Gaebler C, Wang Z, Lorenzi JCC, et al.
Evolution of antibody immunity to SARS-CoV-2.
Science. 2021;370:eabg2863.
doi:10.1126/science.abg2863

11. Swank Z, Senussi Y, Manickas-Hill Z, et al.
Persistent circulating SARS-CoV-2 spike antigen and post-acute COVID-19 sequelae.
Clinical Infectious Diseases. 2023.

12. Proal AD, VanElzakker MB.
Long COVID or post-acute sequelae of COVID-19: proposed pathogenesis.
Infectious Diseases and Clinical Practice. 2021.

13. Stein SR, Ramelli SC, Grazioli A, et al.
SARS-CoV-2 infection and persistence in the human body and brain.
Nature Immunology. 2022.

14. Chertow D, Stein S, Ramelli S, et al.
Persistence of SARS-CoV-2 in tissues and cellular reservoirs.
Nature. 2023.

Gastrointestinal Reservoirs and Microbiome

15. Lamers MM, Beumer J, van der Vaart J, et al.
SARS-CoV-2 productively infects human gut enterocytes.
Science. 2020;369:50–54.
doi:10.1126/science.abc1669

16. Zuo T, Zhang F, Lui GCY, et al.
Alterations in gut microbiota of patients with COVID-19.
Gastroenterology. 2020;159:944–955.
doi:10.1053/j.gastro.2020.05.048

17. Zollner A, Koch R, Jukic A, et al.
Postacute COVID-19 syndrome: persistence of SARS-CoV-2 RNA in intestinal biopsies.
Gastroenterology. 2022.

18. Natarajan A, Zlitni S, Brooks EF, et al.
Gastrointestinal persistence of SARS-CoV-2 RNA after acute infection.
Med. 2022.

Immune Dysregulation

19. Lucas C, Wong P, Klein J, et al.
Longitudinal analyses reveal immunological misfiring in severe COVID-19.
Nature. 2020;584:463–469.

20. Sette A, Crotty S.
Adaptive immunity to SARS-CoV-2 and COVID-19.
Cell. 2021;184:861–880.

21. Peluso MJ, Deeks SG.
Early clues regarding the pathogenesis of long COVID.
Trends in Immunology. 2022.

22. Su Y, Yuan D, Chen DG, et al.
Multiple early factors anticipate post-acute COVID-19 sequelae.
Cell. 2022;185:881–895.
doi:10.1016/j.cell.2022.01.014

Neuroinflammation and Neurological Disease

23. Douaud G, Lee S, Alfaro-Almagro F, et al.
SARS-CoV-2 is associated with changes in brain structure in UK Biobank.
Nature. 2022;604:697–707.
doi:10.1038/s41586-022-04569-5

24. Boldrini M, Canoll PD, Klein RS.
How COVID-19 affects the brain.
Science. 2021;373:1275–1276.

25. Marshall M.
COVID and the brain: neuroinflammation and cognitive effects.
Nature. 2021.

26. Fernández-Castañeda A, Lu P, Geraghty AC, et al.
Mild respiratory COVID can cause multi-lineage neural inflammation.
Cell. 2022;185:2558–2573.

Endothelial Dysfunction and Microvascular Injury

27. Varga Z, Flammer AJ, Steiger P, et al.
Endothelial cell infection and endotheliitis in COVID-19.
Lancet. 2020;395:1417–1418.

28. Ackermann M, Verleden SE, Kuehnel M, et al.
Pulmonary vascular endothelialitis and thrombotic angiopathy in COVID-19.
New England Journal of Medicine. 2020;383:120–128.

29. Libby P, Lüscher T.
COVID-19 is, in the end, an endothelial disease.
European Heart Journal. 2020;41:3038–3044.

Coagulation and Fibrin Abnormalities

30. Connors JM, Levy JH.
COVID-19 and its implications for thrombosis and anticoagulation.
Blood. 2020;135:2033–2040.

31. Pretorius E, Vlok M, Venter C, et al.
Persistent clotting protein pathology in Long COVID.
Cardiovascular Diabetology. 2021.

32. Rauch A, Dupont A, Goutay J, et al.
Coagulation biomarkers and thrombotic complications in COVID-19.
Journal of Thrombosis and Haemostasis. 2020.

Mitochondrial Dysfunction and Metabolic Disease

33. Stefano GB, Ptacek R, Ptackova H, et al.
Selective mitochondrial targeting in COVID-19 pathogenesis.
Medical Science Monitor. 2020.

34. Appelman B, Charlton BT, Goulding RP, et al.
Muscle abnormalities in patients with Long COVID.
Nature Communications. 2024.

35. Nunn AVW, Guy GW, Brodie JS, Bell JD.
Using physiology to understand Long COVID.
Clinical Science. 2022.

Dysautonomia and Autonomic Dysfunction

36. Raj SR, Arnold AC, Barboi A, et al.
Long COVID and autonomic dysfunction.
Journal of the American College of Cardiology. 2021.

37. Dani M, Dirksen A, Taraborrelli P, et al.
Autonomic dysfunction in patients with post-COVID syndrome.
Clinical Medicine. 2021.

Clinical Trials and Therapeutics

38. Hammond J, Leister-Tebbe H, Gardner A, et al.
Oral nirmatrelvir for high-risk patients with COVID-19.
New England Journal of Medicine. 2022;386:1397–1408.

39. RECOVER Initiative.
NIH RECOVER clinical trials program.
National Institutes of Health.

40. Davis HE, McCorkell L, Moore Vogel J, Topol EJ.
Long COVID: research priorities.
Nature Reviews Microbiology. 2023.

Biomarkers and Multi-Omics

41. Su Y, Chen D, Yuan D, et al.
Multi-omics resolution of COVID-19 immune responses.
Cell. 2022.

42. Phetsouphanh C, Darley DR, Wilson DB, et al.
Immunological dysfunction persists for 8 months following acute COVID-19 infection.
Nature Immunology. 2022.

43. Peluso MJ, Deeks SG.
Mechanisms of post-acute COVID-19 syndrome.
Nature Reviews Immunology. 2023.

Rehabilitation and Clinical Management

44. NICE guideline NG188.
COVID-19 rapid guideline: managing the long-term effects of COVID-19.
National Institute for Health and Care Excellence.

45. World Health Organization.
Clinical management of COVID-19: living guideline.

Broad Reviews

46. Davis HE, Assaf GS, McCorkell L, et al.
Characterizing Long COVID in an international cohort.
Lancet. 2021.

47. Nalbandian A, Sehgal K, Gupta A, et al.
Post-acute COVID-19 syndrome.
Nature Medicine. 2021.

48. Topol EJ.
The mechanism of Long COVID.
Nature Reviews Microbiology. 2023.

49. Ballouz T, Menges D, Anagnostopoulos A, et al.
Recovery and persistence after SARS-CoV-2 infection.
BMJ. 2023.

50. Al-Aly Z, Xie Y, Bowe B.
High-dimensional characterization of post-acute sequelae of COVID-19.
Nature Medicine. 2021.

Persistent Viral Antigen, Tissue Reservoirs, and Viral Persistence

51. Chertow D, Stein S, Ramelli S, et al.
SARS-CoV-2 infection and persistence throughout the human body and brain.
Nature. 2023;612:758–767.

52. Stein SR, Ramelli SC, Grazioli A, et al.
SARS-CoV-2 infection and persistence in the human body and brain.
Nature. 2022.

53. Swank Z, Senussi Y, Manickas-Hill Z, et al.
Persistent circulating SARS-CoV-2 spike antigen and post-acute COVID-19 sequelae.
Clinical Infectious Diseases. 2023.

54. Gaebler C, Wang Z, Lorenzi JCC, et al.
Evolution of antibody immunity to SARS-CoV-2.
Science. 2021;370:eabg2863.

55. Turner JS, O’Halloran JA, Kalaidina E, et al.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Nature. 2021;596:109–113.

56. Mehandru S, Merad M.
Pathological sequelae of long-haul COVID.
Nature Immunology. 2022;23:194–202.

57. Proal AD, VanElzakker MB.
Long COVID or post-acute sequelae of COVID-19: proposed pathogenesis and treatment considerations.
Infectious Diseases and Clinical Practice. 2021.

Gastrointestinal Persistence and Gut–Immune Interactions

58. Gaebler C, Wang Z, Lorenzi JCC, et al.
Evolution of antibody immunity to SARS-CoV-2.
Science. 2021.

59. Natarajan A, Zlitni S, Brooks EF, et al.
Gastrointestinal symptoms and SARS-CoV-2 RNA persistence after infection.
Med. 2022.

60. Zollner A, Koch R, Jukic A, et al.
Postacute COVID-19 syndrome is associated with persistence of SARS-CoV-2 RNA in intestinal biopsies.
Gastroenterology. 2022.

61. Cheung KS, Hung IFN, Chan PPY, et al.
Gastrointestinal manifestations of SARS-CoV-2 infection.
Gut. 2020;69:997–1001.

62. Lamers MM, Beumer J, van der Vaart J, et al.
SARS-CoV-2 productively infects human gut enterocytes.
Science. 2020;369:50–54.

63. Zuo T, Zhang F, Lui GCY, et al.
Alterations in gut microbiota of patients with COVID-19.
Gastroenterology. 2020;159:944–955.

64. Yeoh YK, Zuo T, Lui GCY, et al.
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.
Gut. 2021;70:698–706.

Lymph Nodes, Germinal Centers, and Immune Memory

65. Kaneko N, Kuo HH, Boucau J, et al.
Loss of Bcl-6-expressing germinal centers in COVID-19.
Cell. 2020;183:143–157.

66. Laidlaw BJ, Ellebedy AH.
The germinal centre B cell response to SARS-CoV-2.
Nature Reviews Immunology. 2022;22:7–18.

67. Sette A, Crotty S.
Adaptive immunity to SARS-CoV-2 and COVID-19.
Cell. 2021;184:861–880.

68. Turner JS, Kim W, Kalaidina E, et al.
SARS-CoV-2 infection induces long-lived bone marrow plasma cells.
Nature. 2021;595:421–425.

69. Wang Z, Muecksch F, Schaefer-Babajew D, et al.
Naturally enhanced neutralizing breadth after SARS-CoV-2 infection.
Nature. 2021;595:426–431.

Central Nervous System and Neurological Disease

70. Douaud G, Lee S, Alfaro-Almagro F, et al.
SARS-CoV-2 is associated with changes in brain structure in UK Biobank.
Nature. 2022;604:697–707.

71. Fernández-Castañeda A, Lu P, Geraghty AC, et al.
Mild respiratory COVID can cause multi-lineage neural inflammation.
Cell. 2022;185:2558–2573.

72. Boldrini M, Canoll PD, Klein RS.
How COVID-19 affects the brain.
Science. 2021;373:1275–1276.

73. Marshall M.
How COVID-19 affects the brain.
Nature. 2021.

74. Matschke J, Lütgehetmann M, Hagel C, et al.
Neuropathology of patients with COVID-19.
Lancet Neurology. 2020;19:919–929.

75. Reichard RR, Kashani KB, Boire NA, et al.
Neuropathology of COVID-19: a spectrum of vascular and inflammatory changes.
Acta Neuropathologica. 2020.

76. Taquet M, Geddes JR, Husain M, et al.
6-month neurological and psychiatric outcomes after COVID-19.
Lancet Psychiatry. 2021;8:416–427.

Neuroinflammation, Microglia, and Cognitive Dysfunction

77. Heneka MT, Golenbock D, Latz E, et al.
Immediate and long-term consequences of COVID-19 infections for the development of neurological disorders.
Cell. 2020;183:1258–1270.

78. Rhea EM, Logsdon AF, Hansen KM, et al.
The S1 protein of SARS-CoV-2 crosses the blood-brain barrier.
Nature Neuroscience. 2021.

79. Song E, Bartley CM, Chow RD, et al.
Neuroinvasion of SARS-CoV-2 in human and mouse brain.
Journal of Experimental Medicine. 2021.

80. Mierzwa AJ, et al.
Neuroimmune mechanisms in post-acute COVID neurological disease.
Nature Reviews Neurology. 2023.

Endothelium, Vascular Injury, and Microcirculation

81. Varga Z, Flammer AJ, Steiger P, et al.
Endothelial cell infection and endotheliitis in COVID-19.
Lancet. 2020;395:1417–1418.

82. Ackermann M, Verleden SE, Kuehnel M, et al.
Pulmonary vascular endothelialitis and thrombotic angiopathy in COVID-19.
New England Journal of Medicine. 2020;383:120–128.

83. Libby P, Lüscher T.
COVID-19 is, in the end, an endothelial disease.
European Heart Journal. 2020;41:3038–3044.

84. Teuwen LA, Geldhof V, Pasut A, Carmeliet P.
COVID-19: the vasculature unleashed.
Nature Reviews Immunology. 2020;20:389–391.

85. Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ.
Endothelial dysfunction in COVID-19.
Lancet. 2020.

Coagulation, Platelets, and Fibrin Abnormalities

86. Connors JM, Levy JH.
COVID-19 and its implications for thrombosis and anticoagulation.
Blood. 2020;135:2033–2040.

87. Levi M, Thachil J, Iba T, Levy JH.
Coagulation abnormalities and thrombosis in patients with COVID-19.
Lancet Haematology. 2020;7:e438–e440.

88. Pretorius E, Vlok M, Venter C, et al.
Persistent clotting protein pathology in Long COVID.
Cardiovascular Diabetology. 2021.

89. Rauch A, Dupont A, Goutay J, et al.
Coagulation biomarkers and thrombotic complications in COVID-19.
Journal of Thrombosis and Haemostasis. 2020.

90. Zuo Y, Estes SK, Ali RA, et al.
Prothrombotic autoantibodies in COVID-19.
Science Translational Medicine. 2021.

Immune Dysregulation and Autoimmunity

91. Su Y, Yuan D, Chen DG, et al.
Multiple early factors anticipate post-acute COVID-19 sequelae.
Cell. 2022;185:881–895.

92. Phetsouphanh C, Darley DR, Wilson DB, et al.
Immunological dysfunction persists for 8 months following acute COVID-19 infection.
Nature Immunology. 2022;23:210–216.

93. Peluso MJ, Deeks SG.
Mechanisms of post-acute COVID-19 syndrome.
Nature Reviews Immunology. 2023.

94. Wallukat G, Hohberger B, Wenzel K, et al.
Functional autoantibodies against G-protein coupled receptors in COVID-19 patients.
Journal of the American College of Cardiology. 2021.

95. Wang EY, Mao T, Klein J, et al.
Diverse functional autoantibodies in patients with COVID-19.
Nature. 2021.

Biomarkers and Multi-Omics

96. Su Y, Chen D, Yuan D, et al.
Multi-omics resolves a sharp disease-state transition in COVID-19.
Cell. 2022.

97. Filbin MR, Mehta A, Schneider AM, et al.
Longitudinal proteomic analysis of severe COVID-19.
Cell Reports Medicine. 2021.

98. Mick E, Kamm J, Pisco AO, et al.
Upper airway gene expression reveals inflammatory signatures in COVID-19.
Nature Communications. 2020.

99. Lucas C, Klein J, Sundaram ME, et al.
Delayed production of neutralizing antibodies correlates with fatal COVID-19.
Nature. 2021.

100. Altmann DM, Boyton RJ.
Immunity to SARS-CoV-2 and COVID-19 vaccines.
Science. 2022.

Long COVID Epidemiology and Clinical Phenotyping

101. Davis HE, Assaf GS, McCorkell L, et al.
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact.
EClinicalMedicine. 2021;38:101019.

102. Sudre CH, Murray B, Varsavsky T, et al.
Attributes and predictors of long COVID.
Nature Medicine. 2021;27:626–631.

103. Al-Aly Z, Xie Y, Bowe B.
High-dimensional characterization of post-acute sequelae of COVID-19.
Nature Medicine. 2021;27:1730–1738.

104. Xie Y, Choi T, Al-Aly Z.
Long-term outcomes of COVID-19 infection.
Nature Medicine. 2023.

105. Ballouz T, Menges D, Anagnostopoulos A, et al.
Recovery and symptom trajectories after SARS-CoV-2 infection.
BMJ. 2023.

106. Thompson EJ, Williams DM, Walker AJ, et al.
Long COVID burden and symptom persistence following infection.
Lancet Regional Health – Europe. 2022.

107. Perlis RH, Santillana M, Ognyanova K, et al.
Prevalence and correlates of long COVID symptoms.
JAMA Network Open. 2022.

RECOVER Initiative and NIH Long COVID Research

108. RECOVER Initiative.
Researching COVID to Enhance Recovery: NIH Long COVID Research Program.
National Institutes of Health.

109. Daugherty SE, Guo Y, Heath K, et al.
Risk of clinical sequelae after COVID-19 infection.
Nature Medicine. 2021;27:1258–1267.

110. Berger Z, Altiery DE, Assoumou SA, Greenhalgh T.
Long COVID and the need for patient-centered research.
BMJ. 2021.

111. Becker PM.
Clinical characteristics of long COVID.
Nature Reviews Microbiology. 2023.

Cardiovascular Sequelae

112. Xie Y, Xu E, Bowe B, Al-Aly Z.
Long-term cardiovascular outcomes of COVID-19.
Nature Medicine. 2022;28:583–590.

113. Puntmann VO, Carerj ML, Wieters I, et al.
Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19.
JAMA Cardiology. 2020;5:1265–1273.

114. Raman B, Bluemke DA, Lüscher TF, Neubauer S.
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
European Heart Journal. 2022.

115. Jankowski J, Kaliszewski K, Kaczmarek A, et al.
Cardiovascular complications following COVID-19.
Cardiology Research. 2022.

116. Huang C, Huang L, Wang Y, et al.
6-month consequences of COVID-19 in patients discharged from hospital.
Lancet. 2021;397:220–232.

Kidney Injury and Renal Sequelae

117. Bowe B, Xie Y, Xu E, Al-Aly Z.
Kidney outcomes in long COVID.
Journal of the American Society of Nephrology. 2021;32:2851–2862.

118. Nadim MK, Forni LG, Mehta RL, et al.
COVID-19-associated acute kidney injury.
Nature Reviews Nephrology. 2020;16:593–602.

119. Mohamed MM, Lukitsch I, Torres-Ortiz AE, et al.
Acute kidney injury associated with COVID-19.
Kidney International Reports. 2021.

120. Legrand M, Bell S, Forni L, et al.
Pathophysiology of COVID-19-associated acute kidney injury.
Nature Reviews Nephrology. 2021.

Pulmonary and Exercise Physiology

121. Huang L, Yao Q, Gu X, et al.
1-year outcomes in patients recovered from COVID-19.
Lancet Respiratory Medicine. 2022.

122. Sykes DL, Holdsworth L, Jawad N, et al.
Post-COVID-19 symptom burden and respiratory outcomes.
Thorax. 2021.

123. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al.
Respiratory function after COVID-19.
European Respiratory Journal. 2021.

124. Debeaumont D, Boujibar F, Ferrand-Devouge E, et al.
Exercise capacity after COVID-19 infection.
Respiratory Medicine. 2021.

Dysautonomia and POTS-like Syndromes

125. Dani M, Dirksen A, Taraborrelli P, et al.
Autonomic dysfunction in “long COVID”: rationale, physiology and management.
Clinical Medicine. 2021;21:e63–e67.

126. Raj SR, Arnold AC, Barboi A, et al.
Long COVID and autonomic dysfunction: clinical implications.
Journal of the American College of Cardiology. 2021.

127. Blitshteyn S, Whitelaw S.
Postural orthostatic tachycardia syndrome after COVID-19.
Heart Rhythm. 2021.

128. Goldstein DS.
The autonomic nervous system and COVID-19.
Clinical Autonomic Research. 2022.

Neuropathy and Small Fiber Disease

129. Oaklander AL, Mills AJ, Kelley M, et al.
Peripheral neuropathy evaluations in patients with long COVID.
Neurology: Neuroimmunology & Neuroinflammation. 2022.

130. McAlpine LS, Zuberi K, Lacy M, et al.
Small fiber neuropathy following SARS-CoV-2 infection.
Neurology Clinical Practice. 2022.

131. Novak P.
Post COVID-19 syndrome and autonomic dysfunction.
Autonomic Neuroscience. 2021.

Mitochondrial Dysfunction and Cellular Metabolism

132. Nunn AVW, Guy GW, Brodie JS, Bell JD.
Using physiology to understand Long COVID.
Clinical Science. 2022.

133. Appelman B, Charlton BT, Goulding RP, et al.
Muscle abnormalities and exercise intolerance in Long COVID.
Nature Communications. 2024.

134. Barcena C, Valdés-Mas R, Mayoral P, et al.
Metabolic signatures associated with SARS-CoV-2 infection.
Cell Metabolism. 2021.

135. Guarnieri JW, Dybas JM, Fazelinia H, et al.
Long COVID molecular signatures.
Nature Communications. 2023.

Therapeutic Studies and Antivirals

136. Hammond J, Leister-Tebbe H, Gardner A, et al.
Oral nirmatrelvir for high-risk nonhospitalized adults with COVID-19.
New England Journal of Medicine. 2022;386:1397–1408.

137. Reis G, Silva EASM, Silva DCM, et al.
Effect of early treatment with fluvoxamine on COVID-19 outcomes.
Lancet Global Health. 2022.

138. Cao B, Wang Y, Wen D, et al.
A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19.
New England Journal of Medicine. 2020;382:1787–1799.

139. Beigel JH, Tomashek KM, Dodd LE, et al.
Remdesivir for the treatment of COVID-19.
New England Journal of Medicine. 2020;383:1813–1826.

Rehabilitation and Clinical Management

140. NICE.
COVID-19 rapid guideline: managing the long-term effects of COVID-19.
National Institute for Health and Care Excellence.

141. WHO.
Clinical management of COVID-19: living guideline.
World Health Organization.

142. Barker-Davies RM, O’Sullivan O, Senaratne KPP, et al.
The Stanford Hall consensus statement for post-COVID rehabilitation.
British Journal of Sports Medicine. 2020;54:949–959.

143. Wade DT.
Rehabilitation after COVID-19: an evidence-based approach.
Clinical Medicine. 2020.

Future Directions, Precision Medicine, and Systems Biology

144. Topol EJ.
The mechanism of Long COVID.
Nature Reviews Microbiology. 2023.

145. Altmann DM, Whettlock EM, Liu S, et al.
The immunology of Long COVID.
Nature Reviews Immunology. 2023.

146. Davis HE, McCorkell L, Vogel JM, Topol EJ.
Long COVID: major findings, mechanisms and recommendations.
Nature Reviews Microbiology. 2023;21:133–146.

147. Peluso MJ, Deeks SG.
Mechanisms of post-acute COVID-19 syndrome.
Nature Reviews Immunology. 2023.

148. Brodin P.
Immune determinants of COVID-19 disease presentation and severity.
Nature Medicine. 2021.

149. Wherry EJ, Jaffee EM, Warren N, et al.
Understanding immune responses after SARS-CoV-2 infection.
Science. 2021.

150. The Lancet COVID-19 Commission.
Lessons from COVID-19 and priorities for future pandemic preparedness.
Lancet. 2022.

Appendix A. Evidence Tables

Table 1. Proposed SARS-CoV-2 Persistence Sites and Supporting Evidence

Tissue/Compartment	Evidence Reported	Proposed Mechanisms	Current Evidence Strength
Gastrointestinal tract	Viral RNA, nucleocapsid/spike antigen, immune activation reported in intestinal samples after acute infection	Persistent antigen stimulation, gut barrier dysfunction, microbiome disruption	Moderate
Lymphoid tissue	Altered germinal-center responses, persistent immune activation	Dysregulated B-cell maturation, abnormal antibody responses	Moderate
Brain/CNS	Viral RNA/protein reported in selected neuropathological studies; neuroinflammation demonstrated	Microglial activation, endothelial injury, immune-mediated damage	Low–Moderate
Bone marrow	Long-lived immune alterations and plasma-cell responses documented	Persistent immune imprinting, altered hematopoiesis	Low–Moderate
Lung	Persistent inflammatory changes and vascular abnormalities in subsets	Chronic inflammation, endothelial dysfunction	Moderate
Cardiovascular tissue	Endothelial injury and inflammatory changes	Microvascular dysfunction, immune activation	Moderate
Blood/immune cells	Circulating antigen reported in subsets	Persistent antigen exposure, immune activation	Moderate

Table 2. Major Proposed Mechanisms of Long COVID Pathogenesis

Mechanism	Biological Process	Potential Clinical Manifestations
Viral persistence	Continued presence of viral RNA/protein/antigen	Relapsing symptoms, inflammation
Immune dysregulation	Persistent cytokine signaling, altered lymphocyte function	Fatigue, inflammatory symptoms
Autoimmunity	Antibodies directed against host structures	Dysautonomia, neuropathy
Endothelial dysfunction	Vascular inflammation and impaired circulation	Brain fog, exercise intolerance
Microvascular abnormalities	Abnormal coagulation/fibrinolysis pathways	Fatigue, impaired oxygen utilization
Mitochondrial dysfunction	Impaired cellular energy production	Post-exertional malaise
Autonomic dysfunction	Abnormal sympathetic/parasympathetic balance	Tachycardia, dizziness
Tissue fibrosis/remodeling	Persistent injury response	Organ-specific impairment

Table 3. Investigational Biomarkers in Long COVID

Biomarker Category	Examples	Potential Clinical Application
Inflammatory markers	CRP, IL-6, interferon signatures	Identify inflammatory phenotypes
Immune profiling	T-cell exhaustion, B-cell changes	Patient stratification
Autoantibodies	GPCR antibodies, antiphospholipid antibodies	Identify autoimmune subsets
Viral markers	Spike antigen, viral RNA fragments	Detect possible persistence
Coagulation markers	D-dimer, fibrin abnormalities	Identify vascular phenotype
Metabolomics	Altered energy pathways	Identify metabolic dysfunction
Proteomics	Plasma protein signatures	Diagnostic classification
Transcriptomics	Gene-expression profiles	Mechanism discovery

Table 4. Therapeutic Strategies Under Investigation

Therapeutic Category	Examples	Proposed Mechanism	Evidence Status
Antiviral therapy	Nirmatrelvir/ritonavir, remdesivir	Reduce viral persistence	Under investigation
Immunomodulation	JAK inhibitors, monoclonal therapies	Reduce immune activation	Early research
Antihistamine therapy	H1/H2 blockade	Mast-cell pathway modulation	Preliminary
IVIG	Immunoglobulin replacement	Immune regulation	Selected patients
Anticoagulation approaches	Antithrombotic strategies	Reduce vascular abnormalities	Insufficient evidence for routine use
Low-dose naltrexone	Microglial modulation	Reduce neuroinflammation	Early studies
Rehabilitation	Pacing, autonomic rehabilitation	Restore function	Established supportive approach
Neuromodulation	Vagus nerve stimulation	Autonomic/inflammatory regulation	Investigational

Appendix B. Figure Legends

Figure 1. Proposed Model of SARS-CoV-2 Persistence and Long COVID Pathogenesis

Legend:

SARS-CoV-2 infection results in acute viral replication followed by immune activation. In susceptible individuals, viral components may persist within selected anatomical reservoirs including intestinal tissue, lymphoid structures, and other cellular compartments.

Persistent antigen exposure may promote:

chronic immune activation;
inflammatory cytokine production;
endothelial dysfunction;
autoantibody generation;
metabolic impairment.

These processes interact to produce multisystem manifestations including neurological dysfunction, dysautonomia, cardiovascular abnormalities, fatigue, and impaired exercise tolerance.

Figure 2. Immunopathological Pathways in Long COVID

Legend:

The proposed immunological model involves several interacting pathways:

Persistent antigen pathway

Viral proteins → immune stimulation → chronic inflammation

Autoimmune pathway

Molecular mimicry → autoantibodies → tissue dysfunction

Innate immune pathway

Persistent interferon signaling → cytokine activation → chronic symptoms

Vascular pathway

Endothelial injury → impaired microcirculation → tissue hypoxia

Neural pathway

Inflammation + vascular dysfunction → cognitive and neurological symptoms

Figure 3. Precision Medicine Framework for Long COVID

Legend:

Future management is expected to transition from symptom-based treatment toward biological classification.

Patients may be categorized into:

Viral persistence phenotype

Potential therapy:

antiviral approaches

Immune dysregulation phenotype

Potential therapy:

immunomodulation

Autonomic phenotype

Potential therapy:

autonomic rehabilitation

Vascular phenotype

Potential therapy:

endothelial-directed strategies

Neuropathic phenotype

Potential therapy:

neurological treatments

This framework emphasizes individualized therapy based on biological mechanisms.